Macleods 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
24 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimduo (lamivudine/tenofovir disoproxil fumarate) / Cipla, Celltrion, Macleods, Viatris, Sun Pharma, Aurobindo, Hetero
ChiCTR-TRC-14004908: Rilpivirine Versus Efavirenz with Tenofovir and lamivudine's use in treatment-naive adults with HIV-1 infection and injection drug use on Methadone maintenance treatment

Recruiting
4
60
 
taking Rilpivirine RPV+TDF+3TC and methadone ;taking Rilpivirine RPV+TDF+3TC and methadone
Yunnan Provincial Infectious Disease Hospital; Yunnan Provincial Infectious Disease Hospital, Funded by Xian Janssen Pharmaceutical Ltd.
AIDS
 
 
ChiCTR1900022881: Evaluation of Safety and Efficacy with Treatment by Albuvirtide-Based Antiretroviral Regimen in HIV Post-Exposure Prophylaxis

Recruiting
4
300
 
ABT+DTG ;ABT+TDF+3TC ;DTG+TDF+3TC
Chongqing Public Health Medical Center; Chongqing Public Health Medical Center, Self-financing
AIDS
 
 
ChiCTR1800015005: Evaluation of the efficacy and safety of integrase inhibitor in the treatment of acute HIV infection

Recruiting
4
100
 
2NRTIs (TDF+3TC)+DTG ;2NRTIs (TDF+3TC)+EFV or LPV/r
Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University; Level of the institution：, the Mega-Projects of national science research for the 13th Five-Year Plan
HIV infections
 
 
ChiCTR1800015006: Long-term effects of anti-retroviral therapy in acute HIV infection

Recruiting
4
200
 
2NRTIs (TDF+3TC)+EFV or LPV/r
Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University; Level of the institution：, the Mega-Projects of national science research for the 13th Five-Year Plan
HIV infections
 
 
ChiCTR2000034717: Safety and efficacy of switching to DTG plus 3TC regimen from a LPV/ R +TDF+3TC based second line regimen: a real world study from China with extensive experience in the use of LPV/r and TDF regimens (abridged edition)

Recruiting
4
60
 
DTG+3TC
Zhengzhou Sixth People's Hospital; Level of the institution：, Self-raising
AIDS
 
 
PPREPP-SA, NCT07006246: Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa

Active, not recruiting
4
1900
RoW
Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)
Professor Francois Venter, Bill and Melinda Gates Foundation
HIV Infection
11/25
11/25
PrIMO, NCT06158126: UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study

Recruiting
4
621
RoW
Initiating daily oral PrEP during pregnancy, Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC), Already using daily oral PrEP at the time of pregnancy diagnosis, Initiating injectable PrEP during pregnancy, CAB-LA, Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States President's Emergency Plan for AIDS Relief, Ministry of Health, Malawi
Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related
12/26
12/27
NCT04636437: Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

Completed
4
147
US
Doravirine 100 Mg, DOR, Integrase strand transfer inhibitors, INSTI, Tenofovir alafenamide/emtricitabine, TAF, FTC, tenofovir disproxil fumarate/emtricitabine, TDF, FTC
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
10/24
10/24
ChiCTR2400079673: Efficacy and metabolic parameters changing of switching to Ainuovirine, 3TC, and TDF in treatment experienced adults living with HIV due to dyslipidaemia or weight gain: week 48 results

Not yet recruiting
4
200
 
switch to ANV/3TC/TDF
Chengdu Public Health Clinical Medical Centre; Chengdu Public Health Clinical Medical Centre, Jiangsu Aidea pharmaceutical Co.,Ltd.
HIV-1 infection
 
 
ChiCTR2400079814: Efficacy, safety and adherence of switching to Ainuovirine, 3TC, and TDF in treatment experienced adults living with HIV-1 due to CNS symptoms: week 48 results

Not yet recruiting
4
200
 
switch to ANV/3TC/TDF
Chengdu Public Health Clinical Medical Centre; Jiangsu Aidea pharmaceutical Co.,Ltd., Jiangsu Aidea pharmaceutical Co.,Ltd.
HIV infection
 
 
ChiCTR2400082475: Efficacy and effects on metabolic markers of switching to ANV/3TC/TDF single-tablet regimen versus switching to BIC/FTC/TAF regimen in suppressed treatment-experienced HIV-1 infected patients: Week 48 Results of multi-center, randomized Clinical trial

Not yet recruiting
4
462
 
Switch to ANV/3TC/TDF; Switch to BIC/FTC/TAF
The Sixth People's Hospital of Zhengzhou; The Sixth People's Hospital of Zhengzhou, Jiangsu Aidea pharmaceutical Co.,Ltd.
HIV-1 infection
 
 
ChiCTR2500098499: Effects of TDF/3TC/ANV on cardiovascular disease risk score and intestinal microecology in HIV-1 patients with dyslipidemia

Not yet recruiting
4
60
 
Conversion to TDF+3TC+ANV therapy
First Affiliated Hospital of China Medical University; First Affiliated Hospital of China Medical University, National key research and development plan project (2022YFC2304502)
HIV infection
 
 
ChiCTR1800019041: Phase 3 Efficacy and Safety Study of ACC007 Combined with 3TC+TDF in the Treatment of HIV/AIDS

Completed
3
630
 
Oral administration, once a day, ACC007 150mg + EFV placebo 1 tablet + 3TC 300mg + TDF 300mg. Blinding treatment period: Week 0 to Week 48; Open treatment period: Week 48 to Week 96 ;Oral administration, once a day, EFV 600mg + ACC007 placebo 1 tablet + 3TC 300mg + TDF 300mg. Blinding treatment period : Week 0 to Week 48; Open treatment period: Week 48 to Week 96
Beijing You An Hospital, Capital Medical University; Jiangsu Aidea Pharmaceutical Co., Ltd, Self-financing
Non-nucleoside reverse transcriptase inhibitors,and other antiretroviral drugs in combination with HIV/AIDS
 
 
DOVETAIL, NCT06497465: Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Not yet recruiting
3
150
RoW
Dolutegravir 50mg Tab, TIVICAY 50 mg, TIVICAY PD, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Johns Hopkins University, ViiV Healthcare
Tuberculosis, HIV
01/28
01/29
ChiCTR2000031964: A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment (FNC)

Completed
2
172
 
FNC2mg+TDF+EFV+placebo ;oral FNC3mg+TDF+EFV+placebo ;oral FNC4mg+TDF+EFV+placebo ;oral 3TC+TDF+EFV+placebo
Beijing YouAn Hospital, Capital Medical University; Beijing You'An Hospital, Capital Medical University, The sponsors raise the money themselves
acquired immunodeficiency syndrome
 
 
NCT06061536: Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

Recruiting
2
64
RoW
Lipovirtide 10mg, 3TC, TDF, Lipovirtide 40mg, Lipovirtide 60mg, DTG
Shanxi Kangbao Biological Product Co., Ltd., Institute of Pathogen Biology, Chinese Academy of Medical Sciences
HIV
12/24
12/24
ChiCTR1800018007: Clinical Study of Drug- Drug Interaction between ACC007 and (3TC+TDF)

Completed
1
24
 
300mg once a day oral administration of ACC007 tablets with 75mg specification, subjects in Group A are oral administrated with (3TC 300mg+TDF 300mg) from Day1 to Day17, and with the addition of 300mg ACC007 from Day8 to Day17 ;300mg once a day oral administration of ACC007 tablets with 75mg specification, subjects in Group B are oral administrated with 300mg ACC007 from Day1 to Day17, and with the addition of (3TC 300mg+TDF 300mg) from Day11 to Day17
Beijing Di Tan Hospital, Capital Medical University; Jiangsu Aidea Pharmaceutical.Co., Ltd., Self-financing
Non-nucleoside reverse transcriptase inhibitors,and other antiretroviral drugs in combination with HIV/AIDS
 
 
NCT04867798: Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

Completed
N/A
75
RoW
Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet
Makerere University, Massachusetts General Hospital
HIV, Sexually Transmitted Infections, PrEP, Transgender Men
04/23
04/23
dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
PICASSO, NCT06485154: Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

Active, not recruiting
4
100
RoW
TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir, Acriptega
University of Witwatersrand, South Africa, Bill and Melinda Gates Foundation
HIV Prevention
06/26
08/26
MODERATO, NCT04022967: ANRS 12372 Study

Active, not recruiting
3
480
RoW
dolutegravir, atazanavir boosted with ritonavir, tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir, Lamivudine
ANRS, Emerging Infectious Diseases, Mylan Laboratories
HIV-1-infection
02/25
02/25
NCT05630872: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Active, not recruiting
2
30
RoW
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM, 2HPM
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Mylan Inc.
HIV-associated Tuberculosis
05/25
09/25
NCT04311944: Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

Not yet recruiting
N/A
242
NA
Early fast-track care, Standard (deferred fast-track) care
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Weill Medical College of Cornell University, Florida International University
HIV-1-infection
02/22
05/22
NCT04050449: Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

Completed
N/A
1339
RoW
AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), United States President's Emergency Plan for AIDS Relief
HIV-1-infection
03/23
03/23
ChiCTR2200061677: Impact of different antiretroviral therapy (ART) regimens on lipid metabolism in people living with HIV

Not yet recruiting
N/A
180
 
EVG/c/TAF/FTC ;B/FTC/TAF ;DTG/3TC ;DTG/3TC/TDF ;DTG/FTC/TDF ;TDF/3TC/EFV
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, National Special Research Program for Important Infectious Diseases
AIDS
 
 
Duovir N (lamivudine/zidovudine/nevirapine) / Hetero, Aurobindo, Viatris, Strides Pharma Science, Macleods, Cipla
No trials found
lamivudine/stavudine / Hetero, Macleods, Cipla, Strides Pharma Science
No trials found
lamivudine/stavudine/nevirapine / Hetero, Macleods, Cipla, Strides Pharma Science, Aurobindo, Emcure
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimduo (lamivudine/tenofovir disoproxil fumarate) / Cipla, Celltrion, Macleods, Viatris, Sun Pharma, Aurobindo, Hetero
ChiCTR-TRC-14004908: Rilpivirine Versus Efavirenz with Tenofovir and lamivudine's use in treatment-naive adults with HIV-1 infection and injection drug use on Methadone maintenance treatment

Recruiting
4
60
 
taking Rilpivirine RPV+TDF+3TC and methadone ;taking Rilpivirine RPV+TDF+3TC and methadone
Yunnan Provincial Infectious Disease Hospital; Yunnan Provincial Infectious Disease Hospital, Funded by Xian Janssen Pharmaceutical Ltd.
AIDS
 
 
ChiCTR1900022881: Evaluation of Safety and Efficacy with Treatment by Albuvirtide-Based Antiretroviral Regimen in HIV Post-Exposure Prophylaxis

Recruiting
4
300
 
ABT+DTG ;ABT+TDF+3TC ;DTG+TDF+3TC
Chongqing Public Health Medical Center; Chongqing Public Health Medical Center, Self-financing
AIDS
 
 
ChiCTR1800015005: Evaluation of the efficacy and safety of integrase inhibitor in the treatment of acute HIV infection

Recruiting
4
100
 
2NRTIs (TDF+3TC)+DTG ;2NRTIs (TDF+3TC)+EFV or LPV/r
Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University; Level of the institution：, the Mega-Projects of national science research for the 13th Five-Year Plan
HIV infections
 
 
ChiCTR1800015006: Long-term effects of anti-retroviral therapy in acute HIV infection

Recruiting
4
200
 
2NRTIs (TDF+3TC)+EFV or LPV/r
Key Laboratory of AIDS Immunology of National Health and Family Planning Commission, Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University; Level of the institution：, the Mega-Projects of national science research for the 13th Five-Year Plan
HIV infections
 
 
ChiCTR2000034717: Safety and efficacy of switching to DTG plus 3TC regimen from a LPV/ R +TDF+3TC based second line regimen: a real world study from China with extensive experience in the use of LPV/r and TDF regimens (abridged edition)

Recruiting
4
60
 
DTG+3TC
Zhengzhou Sixth People's Hospital; Level of the institution：, Self-raising
AIDS
 
 
PPREPP-SA, NCT07006246: Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa

Active, not recruiting
4
1900
RoW
Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)
Professor Francois Venter, Bill and Melinda Gates Foundation
HIV Infection
11/25
11/25
PrIMO, NCT06158126: UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study

Recruiting
4
621
RoW
Initiating daily oral PrEP during pregnancy, Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC), Already using daily oral PrEP at the time of pregnancy diagnosis, Initiating injectable PrEP during pregnancy, CAB-LA, Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States President's Emergency Plan for AIDS Relief, Ministry of Health, Malawi
Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related
12/26
12/27
NCT04636437: Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide

Completed
4
147
US
Doravirine 100 Mg, DOR, Integrase strand transfer inhibitors, INSTI, Tenofovir alafenamide/emtricitabine, TAF, FTC, tenofovir disproxil fumarate/emtricitabine, TDF, FTC
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
10/24
10/24
ChiCTR2400079673: Efficacy and metabolic parameters changing of switching to Ainuovirine, 3TC, and TDF in treatment experienced adults living with HIV due to dyslipidaemia or weight gain: week 48 results

Not yet recruiting
4
200
 
switch to ANV/3TC/TDF
Chengdu Public Health Clinical Medical Centre; Chengdu Public Health Clinical Medical Centre, Jiangsu Aidea pharmaceutical Co.,Ltd.
HIV-1 infection
 
 
ChiCTR2400079814: Efficacy, safety and adherence of switching to Ainuovirine, 3TC, and TDF in treatment experienced adults living with HIV-1 due to CNS symptoms: week 48 results

Not yet recruiting
4
200
 
switch to ANV/3TC/TDF
Chengdu Public Health Clinical Medical Centre; Jiangsu Aidea pharmaceutical Co.,Ltd., Jiangsu Aidea pharmaceutical Co.,Ltd.
HIV infection
 
 
ChiCTR2400082475: Efficacy and effects on metabolic markers of switching to ANV/3TC/TDF single-tablet regimen versus switching to BIC/FTC/TAF regimen in suppressed treatment-experienced HIV-1 infected patients: Week 48 Results of multi-center, randomized Clinical trial

Not yet recruiting
4
462
 
Switch to ANV/3TC/TDF; Switch to BIC/FTC/TAF
The Sixth People's Hospital of Zhengzhou; The Sixth People's Hospital of Zhengzhou, Jiangsu Aidea pharmaceutical Co.,Ltd.
HIV-1 infection
 
 
ChiCTR2500098499: Effects of TDF/3TC/ANV on cardiovascular disease risk score and intestinal microecology in HIV-1 patients with dyslipidemia

Not yet recruiting
4
60
 
Conversion to TDF+3TC+ANV therapy
First Affiliated Hospital of China Medical University; First Affiliated Hospital of China Medical University, National key research and development plan project (2022YFC2304502)
HIV infection
 
 
ChiCTR1800019041: Phase 3 Efficacy and Safety Study of ACC007 Combined with 3TC+TDF in the Treatment of HIV/AIDS

Completed
3
630
 
Oral administration, once a day, ACC007 150mg + EFV placebo 1 tablet + 3TC 300mg + TDF 300mg. Blinding treatment period: Week 0 to Week 48; Open treatment period: Week 48 to Week 96 ;Oral administration, once a day, EFV 600mg + ACC007 placebo 1 tablet + 3TC 300mg + TDF 300mg. Blinding treatment period : Week 0 to Week 48; Open treatment period: Week 48 to Week 96
Beijing You An Hospital, Capital Medical University; Jiangsu Aidea Pharmaceutical Co., Ltd, Self-financing
Non-nucleoside reverse transcriptase inhibitors,and other antiretroviral drugs in combination with HIV/AIDS
 
 
DOVETAIL, NCT06497465: Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment

Not yet recruiting
3
150
RoW
Dolutegravir 50mg Tab, TIVICAY 50 mg, TIVICAY PD, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Johns Hopkins University, ViiV Healthcare
Tuberculosis, HIV
01/28
01/29
ChiCTR2000031964: A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment (FNC)

Completed
2
172
 
FNC2mg+TDF+EFV+placebo ;oral FNC3mg+TDF+EFV+placebo ;oral FNC4mg+TDF+EFV+placebo ;oral 3TC+TDF+EFV+placebo
Beijing YouAn Hospital, Capital Medical University; Beijing You'An Hospital, Capital Medical University, The sponsors raise the money themselves
acquired immunodeficiency syndrome
 
 
NCT06061536: Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

Recruiting
2
64
RoW
Lipovirtide 10mg, 3TC, TDF, Lipovirtide 40mg, Lipovirtide 60mg, DTG
Shanxi Kangbao Biological Product Co., Ltd., Institute of Pathogen Biology, Chinese Academy of Medical Sciences
HIV
12/24
12/24
ChiCTR1800018007: Clinical Study of Drug- Drug Interaction between ACC007 and (3TC+TDF)

Completed
1
24
 
300mg once a day oral administration of ACC007 tablets with 75mg specification, subjects in Group A are oral administrated with (3TC 300mg+TDF 300mg) from Day1 to Day17, and with the addition of 300mg ACC007 from Day8 to Day17 ;300mg once a day oral administration of ACC007 tablets with 75mg specification, subjects in Group B are oral administrated with 300mg ACC007 from Day1 to Day17, and with the addition of (3TC 300mg+TDF 300mg) from Day11 to Day17
Beijing Di Tan Hospital, Capital Medical University; Jiangsu Aidea Pharmaceutical.Co., Ltd., Self-financing
Non-nucleoside reverse transcriptase inhibitors,and other antiretroviral drugs in combination with HIV/AIDS
 
 
NCT04867798: Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

Completed
N/A
75
RoW
Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet
Makerere University, Massachusetts General Hospital
HIV, Sexually Transmitted Infections, PrEP, Transgender Men
04/23
04/23
dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
PICASSO, NCT06485154: Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial

Active, not recruiting
4
100
RoW
TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir, Acriptega
University of Witwatersrand, South Africa, Bill and Melinda Gates Foundation
HIV Prevention
06/26
08/26
MODERATO, NCT04022967: ANRS 12372 Study

Active, not recruiting
3
480
RoW
dolutegravir, atazanavir boosted with ritonavir, tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir, Lamivudine
ANRS, Emerging Infectious Diseases, Mylan Laboratories
HIV-1-infection
02/25
02/25
NCT05630872: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Active, not recruiting
2
30
RoW
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM, 2HPM
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Mylan Inc.
HIV-associated Tuberculosis
05/25
09/25
NCT04311944: Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

Not yet recruiting
N/A
242
NA
Early fast-track care, Standard (deferred fast-track) care
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, Brigham and Women's Hospital, Weill Medical College of Cornell University, Florida International University
HIV-1-infection
02/22
05/22
NCT04050449: Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

Completed
N/A
1339
RoW
AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), United States President's Emergency Plan for AIDS Relief
HIV-1-infection
03/23
03/23
ChiCTR2200061677: Impact of different antiretroviral therapy (ART) regimens on lipid metabolism in people living with HIV

Not yet recruiting
N/A
180
 
EVG/c/TAF/FTC ;B/FTC/TAF ;DTG/3TC ;DTG/3TC/TDF ;DTG/FTC/TDF ;TDF/3TC/EFV
The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, National Special Research Program for Important Infectious Diseases
AIDS
 
 
Duovir N (lamivudine/zidovudine/nevirapine) / Hetero, Aurobindo, Viatris, Strides Pharma Science, Macleods, Cipla
No trials found
lamivudine/stavudine / Hetero, Macleods, Cipla, Strides Pharma Science
No trials found
lamivudine/stavudine/nevirapine / Hetero, Macleods, Cipla, Strides Pharma Science, Aurobindo, Emcure
No trials found

Download Options